Literature DB >> 15157363

Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques.

Therese M McGinn1, Qing Wei, Jackie Stallworth, Patricia N Fultz.   

Abstract

Human T cell lymphotropic virus type 1 (HTLV-I) is causally linked to adult T cell leukemia/lymphoma (ATL) and a chronic progressive neurological disease, HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A nonhuman primate model that reproduces disease symptoms seen in HTLV-I-infected humans might facilitate identification of initial immune responses to the virus and an understanding of pathogenic mechanisms in HTLV-I-related disease. Previously, we showed that infection of pig-tailed macaques with HTLV-I(ACH) is associated with multiple signs of disease characteristic of both HAM/TSP and ATL. We report here that within the first few weeks after HTLV-I(ACH) infection of pig-tailed macaques, serum concentrations of interferon (IFN)-alpha increased and interleukin-12 decreased transiently, levels of nitric oxide were elevated, and activation of CD4(+) and CD8(+) lymphocytes and CD16(+) natural killer cells in peripheral blood were observed. HTLV-I(ACH) infection elicited virus-specific antibodies in all four animals within 4 to 6 weeks; however, Tax-specific lymphoproliferative responses were not detected until 25-29 weeks after infection in all four macaques. IFN-gamma production by peripheral blood cells stimulated with a Tax or Gag peptide was detected to varying degrees in all four animals by ELISPOT assay. Peripheral blood lymphocytes from one animal that developed only a marginal antigen-specific cellular response were unresponsive to mitogen stimulation during the last few weeks preceding its death from a rapidly progressive disease syndrome associated with HTLV-I(ACH) infection of pig-tailed macaques. The results show that during the first few months after HTLV-I(ACH) infection, activation of both innate and adaptive immunity, limited virus-specific cellular responses, sustained immune system activation, and, in some cases, immunodeficiency were evident. Thus, this animal model might be valuable for understanding early stages of infection and causes of immune system dysregulation in HTLV-I-infected humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15157363     DOI: 10.1089/088922204323048195

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

2.  Constitutive release of IFNγ and IL2 from peripheral blood mononuclear cells of rhesus macaques (Macaca mulatta) infected with simian T-lymphotropic virus type 1.

Authors:  JoAnn L Yee; Nestor A Montiel; Amir Ardeshir; Amir Ardeshr; Nicholas W Lerche
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

3.  Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV- and SHIV-infected macaques.

Authors:  R Keith Reeves; Qing Wei; Jackie Stallworth; Patricia N Fultz
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

4.  Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies.

Authors:  Xiaoxing Qiu; Priscilla Swanson; Ka-Cheung Luk; Bailin Tu; Francois Villinger; Jaydip Das Gupta; Robert H Silverman; Eric A Klein; Sushil Devare; Gerald Schochetman; John Hackett
Journal:  Retrovirology       Date:  2010-08-17       Impact factor: 4.602

Review 5.  Animal Models Utilized in HTLV-1 Research.

Authors:  Amanda R Panfil; Jacob J Al-Saleem; Patrick L Green
Journal:  Virology (Auckl)       Date:  2013-11-18

Review 6.  STLV-1 as a model for studying HTLV-1 infection.

Authors:  Brice Jégado; Fatah Kashanchi; Hélène Dutartre; Renaud Mahieux
Journal:  Retrovirology       Date:  2019-12-16       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.